Natl Toxicol Program Tech Rep Ser. 1993 Feb;408:1-260.
Mercuric chloride is an inorganic compound that has been used in agriculture as a fungicide, in medicine as a topical antiseptic and disinfectant, and in chemistry as an intermediate in the production of other mercury compounds. The widespread use of mercury has resulted in increased levels of mercury in rivers and lakes. Mercuric chloride was evaluated in toxicity and carcinogenicity studies because of its extensive use and its occurrence as an environmental pollutant, and because of the lack of adequate long-term rodent studies. Toxicology and carcinogenesis studies were conducted by administering mercuric chloride (greater than 99% pure) in deionized water by gavage to groups of F344 rats or B6C3F1 mice for 16 days, 6 months, and 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium (strains TA98, TA100, TA1535, and TA1537), in mouse lymphoma L5178Y cells, in Chinese hamster ovary cells, and in Drosophila melanogaster. 16-DAY STUDIES: Groups of five rats of each sex received 0, 1.25, 2.5, 5, 10, or 20 mg mercuric chloride/kg body weight and groups of five mice of each sex received 0, 5, 10, 20, 40, or 80 mg/kg in deionized water by gavage for 12 dose days. Two male rats in the 20 mg/kg group died in the first week, as did all male and four female mice from the 80 mg/kg group and one male mouse from the 40 mg/kg group. The final mean body weight of male rats receiving 20 mg/kg was 10% lower than that of the controls; the final mean body weight of 20 mg/kg females was 9% lower than that of the controls. Final mean body weights and body weight gains of dosed mice were similar to those of the controls. Absolute and relative kidney weights of male rats receiving 2.5 mg/kg or greater doses and of female rats administered 5 mg/kg or more were significantly greater than those of the controls. Absolute kidney weights of mice were significantly increased in all male dose groups and in the 40 mg/kg female dose group; relative kidney weights of dosed male and female mice were significantly greater than the controls. Analysis of kidney, liver, and brain tissues for mercury residues revealed that the highest mercury concentration was in the kidneys of rats and mice. Acute renal tubule nephropathy occurred in dosed rats and was slightly more severe in males than in females. Chemical-related lesions in mice included renal tubule necrosis, inflammation and necrosis of the forestomach, and necrosis of the glandular stomach. 6-MONTH STUDIES: Groups of 10 rats of each sex received 0, 0.312, 0.625, 1.25, 2.5, or 5 mg mercuric chloride/kg body weight in deionized water by gavage for 26 weeks. Groups of 10 mice of each sex received 0, 1.25, 2.5, 5, 10, or 20 mg/kg in deionized water by gavage for 26 weeks (males) or 27 weeks (females). No deaths related to mercuric chloride administration occurred in rats or mice. Mean body weight gains of male rats that received 5 mg/kg and all female rat dose groups that received 0.625 mg/kg or greater were significantly lower than the controls. The final mean body weight and body weight gain of male mice in the 20 mg/kg group were significantly lower than those of the controls; final mean body weights and body weight gains of other dosed male mice and all dosed female mice were similar to those of the controls. Absolute and relative kidney weights of all dosed male rats and of female rats that received 0.625 mg/kg or greater were significantly greater than those of the controls. In male mice, absolute kidney weights in the three highest dose groups were significantly increased; no biologically significant differences in organ weights occurred in female mice. Analysis of kidney, liver, and brain tissues for mercury residues revealed the highest mercury concentration in the kidneys of rats and mice. The severity of chronic nephropathy increased with dose in male rats. Cytoplasmic vacuolation of renal tubule epithelial cells was observed in male mice in the 5, 10, and 20 mg/kg groups. No histopathologic changes in female mice were related to chemical exposure. 2-YEAR STUDIES: Groups YEAR STUDIES: Groups of 60 rats of each sex received 0, 2.5, or 5 mg mercuric chloride/kg body weight and groups of 60 mice of each sex received 0, 5, or 10 mg/kg in deionized water by gavage 5 days per week for 2 years. The doses were based on decreased weight gains in rats receiving 10 and 20 mg/kg and the decreased weight in male mice receiving 40 mg/kg during the 16-day studies, and on the decreased weight gains and toxicity results seen in the 6-month studies. Increased absolute and relative kidney weights in rats and male mice in the 6-month studies and degenerative renal changes suggested that higher dose levels would result in inadequate survival rates for a 2-year study. 15-Month Interim Evaluations: Relative kidney weights were significantly increased in dosed rats and female mice. The severity of nephropathy was increased in male rats, but not in females. High-dose male and female rats had minimal to mild hyperplasia of the basal cell layer in the forestomach epithelium (diagnosed as acanthosis); this lesion was not found in control or low-dose rats. Male mice had an increased severity of vacuolation of the renal tubule epithelium; no chemical-related lesions occurred in the kidneys of females. The incidence of inflammation of the olfactory epithelium lining the nasal cavity increased in male and female high-dose mice. Survival, Body Weights, and Clinical Signs: Survival of dosed male rats was lower than that of the controls (26/50, 10/50, 5/50); survival of dosed female rats was similar to that of the controls (35/50, 28/49, 30/50). Although more than 60% of the mice in each dose group survived to study end, survival rates of high-dose male mice and dosed female mice were lower than those of the controls (males: 36/50, 36/50, 31/50; females: 41/50, 35/50, 31/50). The final mean body weights of high-dose male and female rats were 15% and 14% lower than controls, respectively. The mean body weight of low-dose female rats was generally similar to controls throughout the 2-year study; the mean body weight of low-dose male rats was similar to that of the control through week 89. In mice, mean body weights of all male and female dose groups were similar to those of the controls throughout the studies. Pathology Findings: Chronic nephropathy appeared to develop at an accelerated rate and led to decreased survival in both dosed male rat groups. Secondary effects of renal dysfunction in dosed male rats resulted in increased incidences of fibrous osteodystrophy of the bone, mineralization of various tissues, and parathyroid gland hyperplasia. Based on evaluations of single and step sections, the incidence of renal tubule hyperplasia was increased in high-dose male rats (control, 3/50; high-dose, 10/50), but the incidences of renal tubule adenoma in high-dose and control males were similar (4/50, 5/50). Renal tubule hyperplasia was also slightly increased in high-dose female rats (2/50, 5/50) and adenomas were seen in high-dose females, but not in controls (0/50, 2/50). Incidences of forestomach hyperplasia in rats were markedly increased in dosed males (3/49, 16/50, 35/50) and high-dose females (5/50, 5/49, 20/50). Squamous cell papillomas of the forestomach were found in 3 low-dose and 12 high-dose males and in 2 high-dose females. No squamous cell carcinomas were found. The incidence of thyroid follicular cell carcinoma was marginally increased in high-dose male rats (1/50, 2/50, 6/50). However, a corresponding increased incidence in follicular cell adenomas (1/50, 4/50, 0/50) or hyperplasia (2/50, 4/50, 2/50) in males did not occur, and the overall incidence of follicular cell neoplasms was not significantly increased (2/50, 6/50, 6/50). The incidence of nasal mucosa inflammation in male and female rats was increased in the high-dose groups (male: 9/50, 8/47, 18/50; female: 0/49, 5/49, 15/50) and may have been related to chemical administration. The incidences of mammary gland fibroadenomas were significantly decreased in dosed female rats (15/50, 5/48, 2/50). The incidence and severity of nephropathy were increased in dosed mice; secondary effects of renal dysfunction did not occur. Renal tubule hyperplasia was found in one control and two high-dose male mice. Two renal tubule adenomas and one renal tubule adenocarcinoma were seen in high-dose male mice. Additional step sections revealed focal hyperplasia in another control male; no additional renal tubule neoplasms were found in high-dose or control males. Proliferative lesions of the renal tubule epithelium were not found in female mice. The incidence of metaplasia of the olfactory epithelium increased with dose in male and female mice. No other biologically significant lesions were found. GENETIC TOXICOLOGY: Mercuric chloride was not mutagenic in Salmonella typhimurium strains TA100, TA1535, TA1537, or TA98 with or without exogenous metabolic activation (S9). Induction of sex-linked recessive lethal mutations in germ cells of male Drosophila melanogaster did not occur when mercuric chloride was administered in feed or by injection. However, positive results were obtained in mutagenicity tests with mammalian cells. In the absence of S9, mercuric chloride induced trifluorothymidine resistance in mouse L5178Y cells and chromosomal aberrations in Chinese hamster ovary cells. In the Chinese hamster ovary cell test for induction of sister chromatid exchanges, mercuric chloride produced a negative response without S9 and a weakly positive response in the presence of S9. CONCLUSIONS: Under the conditions of these 2-year gavage studies, there was some evidence of carcinogenic activity of mercuric chloride in male F344 rats based on the increased incidence of squamous cell papillomas of the forestomach. Marginally increased incidences of thyroid follicular cell adenomas and carcinomas may have been related to mercuric chloride exposure. There was equivocal evidence of carcinogenic activity of mercuric chloride in female F344 rats based on two squamous cell papillomas of the forestomach. There was equivocal evidence of carcinogenic activity of mercuric chloride in male B6C3F1 mice based on the occurrences of two renal tubule adenomas and one renal tubule adenocarcinoma. There was no evidence of carcinogenic activity of mercuric chloride in female B6C3F1 mice receiving 5 or 10 mg/kg. Nonneoplastic lesions associated with exposure to mercuric chloride included increased severity of nephropathy in male rats and male and female mice. There was an increased incidence of renal tubule hyperplasia in male rats. The incidence of forestomach hyperplasia was increased in dosed male and female rats. Increased incidences of nasal mucosa inflammation were associated with mercuric chloride administration in rats. Increased incidences of olfactory epithelial metaplasia in mice were also associated with mercuric chloride administration. Synonyms: Abavit B, calochlor, corrosive sublimate, dichloromercury, mercuric bichloride, mercury chloride, mercury (II) chloride, mercury bichloride, mercury perchloride, sublimate, sulem, bichloride of mercury, corrosive mercury chloride, perchloride of mercury, mercury dichloride Trade name: Fungchex
氯化汞是一种无机化合物,曾在农业中用作杀菌剂,在医学中用作局部防腐剂和消毒剂,在化学领域中用作生产其他汞化合物的中间体。汞的广泛使用导致河流和湖泊中的汞含量增加。由于氯化汞的广泛使用及其作为环境污染物的存在,以及缺乏足够的长期啮齿动物研究,因此对其进行了毒性和致癌性研究。通过将纯度大于99%的氯化汞用去离子水配制成溶液,每周5天经口灌胃给予F344大鼠或B6C3F1小鼠,持续16天、6个月和2年,进行了毒理学和致癌作用研究。在鼠伤寒沙门氏菌(TA98、TA100、TA1535和TA1537菌株)、小鼠淋巴瘤L5178Y细胞、中国仓鼠卵巢细胞和黑腹果蝇中进行了遗传毒理学研究。
16天研究:每组五只雄性和雌性大鼠分别接受0、1.25、2.5、5、10或20mg/kg体重的氯化汞,每组五只雄性和雌性小鼠分别接受0、5、10、20、40或80mg/kg的氯化汞,用去离子水经口灌胃,给药12天。20mg/kg组的两只雄性大鼠在第一周死亡,80mg/kg组的所有雄性和四只雌性小鼠以及40mg/kg组的一只雄性小鼠也死亡。接受20mg/kg的雄性大鼠的最终平均体重比对照组低10%;接受20mg/kg的雌性大鼠的最终平均体重比对照组低9%。给药小鼠的最终平均体重和体重增加与对照组相似。接受2.5mg/kg或更高剂量的雄性大鼠以及接受5mg/kg或更高剂量的雌性大鼠的绝对和相对肾脏重量显著高于对照组。所有雄性给药组和40mg/kg雌性给药组的小鼠绝对肾脏重量显著增加;给药雄性和雌性小鼠的相对肾脏重量显著高于对照组。对肾脏、肝脏和脑组织进行汞残留分析,结果显示大鼠和小鼠肾脏中的汞浓度最高。给药大鼠出现急性肾小管肾病,雄性比雌性略严重。小鼠的化学相关病变包括肾小管坏死、前胃炎症和坏死以及腺胃坏死。
6个月研究:每组十只雄性和雌性大鼠分别接受0、0.312、0.625、1.25、2.5或5mg/kg体重的氯化汞,用去离子水经口灌胃,持续26周。每组十只雄性和雌性小鼠分别接受0、1.25、2.5、5、10或20mg/kg的氯化汞,用去离子水经口灌胃,雄性持续26周,雌性持续27周。大鼠或小鼠中未发生与氯化汞给药相关的死亡。接受5mg/kg的雄性大鼠和接受0.625mg/kg或更高剂量的所有雌性大鼠组的平均体重增加显著低于对照组。20mg/kg组雄性小鼠的最终平均体重和体重增加显著低于对照组;其他给药雄性小鼠和所有给药雌性小鼠的最终平均体重和体重增加与对照组相似。所有给药雄性大鼠以及接受0.625mg/kg或更高剂量的雌性大鼠的绝对和相对肾脏重量显著高于对照组。在雄性小鼠中,三个最高剂量组的绝对肾脏重量显著增加;雌性小鼠的器官重量未出现生物学上的显著差异。对肾脏、肝脏和脑组织进行汞残留分析,结果显示大鼠和小鼠肾脏中的汞浓度最高。雄性大鼠慢性肾病的严重程度随剂量增加而增加。在5、10和20mg/kg组的雄性小鼠中观察到肾小管上皮细胞的细胞质空泡化。雌性小鼠未出现与化学暴露相关的组织病理学变化。
2年研究:每组六十只雄性和雌性大鼠分别接受0、2.5或5mg/kg体重的氯化汞,每组六十只雄性和雌性小鼠分别接受0、5或10mg/kg的氯化汞,用去离子水经口灌胃,每周5天,持续2年。剂量基于16天研究中接受10和20mg/kg的大鼠体重增加减少以及接受40mg/kg的雄性小鼠体重下降,以及6个月研究中观察到的体重增加减少和毒性结果。6个月研究中大鼠和雄性小鼠的绝对和相对肾脏重量增加以及退行性肾脏变化表明,更高剂量水平会导致2年研究的存活率不足。
15个月中期评估:给药大鼠和雌性小鼠的相对肾脏重量显著增加。雄性大鼠肾病的严重程度增加,雌性则未增加。高剂量雄性和雌性大鼠的前胃上皮基底细胞层有轻度至中度增生(诊断为棘皮症);对照组或低剂量大鼠未发现此病变。雄性小鼠肾小管上皮细胞空泡化的严重程度增加;雌性小鼠肾脏未出现与化学相关的病变。鼻腔内衬嗅上皮的炎症发生率在高剂量雄性和雌性小鼠中增加。
存活率、体重和临床症状:给药雄性大鼠的存活率低于对照组(26/50、10/50、5/50);给药雌性大鼠的存活率与对照组相似(35/50、28/49、30/50)。尽管每个剂量组中超过60%的小鼠存活至研究结束,但高剂量雄性小鼠和给药雌性小鼠的存活率低于对照组(雄性:36/50、36/50、31/50;雌性:41/50、35/50、31/50)。高剂量雄性和雌性大鼠的最终平均体重分别比对照组低15%和14%。在整个2年研究中,低剂量雌性大鼠的平均体重通常与对照组相似;低剂量雄性大鼠的平均体重在第89周前与对照组相似。在小鼠中,所有雄性和雌性剂量组的平均体重在整个研究过程中与对照组相似。
慢性肾病似乎以加速的速度发展,导致两个给药雄性大鼠组的存活率下降。给药雄性大鼠肾功能障碍的继发效应导致骨纤维性骨营养不良、各种组织矿化和甲状旁腺增生的发生率增加。根据单切片和连续切片评估,高剂量雄性大鼠肾小管增生的发生率增加(对照组,3/50;高剂量组,10/50),但高剂量和对照组雄性大鼠肾小管腺瘤的发生率相似(4/50、5/50)。高剂量雌性大鼠肾小管增生也略有增加(2/50、5/50),高剂量雌性大鼠可见腺瘤,而对照组未见(0/50、2/50)。给药雄性大鼠(3/49、16/50、35/50)和高剂量雌性大鼠(5/50、5/49、20/50)的前胃增生发生率显著增加。在3只低剂量和12只高剂量雄性大鼠以及2只高剂量雌性大鼠中发现了前胃鳞状细胞乳头瘤。未发现鳞状细胞癌。高剂量雄性大鼠甲状腺滤泡细胞癌的发生率略有增加(1/50、2/50、6/50)。然而,雄性大鼠滤泡细胞腺瘤(1/50、4/50、0/50)或增生(2/50、4/50、2/50)的发生率并未相应增加,滤泡细胞肿瘤的总体发生率也未显著增加(2/50、6/50、6/50)。高剂量组雄性和雌性大鼠鼻黏膜炎症的发生率增加(雄性:9/50、8/47、18/50;雌性:0/49、5/49、15/50),可能与化学给药有关。给药雌性大鼠乳腺纤维腺瘤的发生率显著降低(15/50、5/48、2/50)。给药小鼠肾病的发生率和严重程度增加;未出现肾功能障碍的继发效应。在一只对照雄性和两只高剂量雄性小鼠中发现肾小管增生。在高剂量雄性小鼠中发现了两个肾小管腺瘤和一个肾小管腺癌。额外的连续切片显示另一只对照雄性有局灶性增生;在高剂量或对照雄性中未发现其他肾小管肿瘤。雌性小鼠未发现肾小管上皮的增殖性病变。雄性和雌性小鼠嗅上皮化生的发生率随剂量增加。未发现其他生物学上显著的病变。
氯化汞在有或无外源性代谢激活(S9)的情况下,对鼠伤寒沙门氏菌TA100、TA1535、TA1537或TA98菌株均无致突变性。当通过饲料或注射给予氯化汞时,未在雄性黑腹果蝇的生殖细胞中诱导性连锁隐性致死突变。然而,在哺乳动物细胞的致突变性试验中获得了阳性结果。在没有S9的情况下,氯化汞在小鼠L5178Y细胞中诱导三氟胸苷抗性,并在中国仓鼠卵巢细胞中诱导染色体畸变。在中国仓鼠卵巢细胞姐妹染色单体交换诱导试验中,氯化汞在没有S9时产生阴性反应,在有S9时产生弱阳性反应。
在这些2年经口灌胃研究的条件下,基于前胃鳞状细胞乳头瘤发生率增加,有一些证据表明氯化汞对雄性F344大鼠具有致癌活性。甲状腺滤泡细胞腺瘤和癌的发生率略有增加可能与氯化汞暴露有关。基于两只前胃鳞状细胞乳头瘤,有不确定的证据表明氯化汞对雌性F344大鼠具有致癌活性。基于两个肾小管腺瘤和一个肾小管腺癌的发生,有不确定的证据表明氯化汞对雄性B6C3F1小鼠具有致癌活性。接受5或10mg/kg剂量的雌性B6C3F1小鼠中没有氯化汞致癌活性的证据。与氯化汞暴露相关的非肿瘤性病变包括雄性大鼠以及雄性和雌性小鼠肾病严重程度增加。雄性大鼠肾小管增生的发生率增加。给药雄性和雌性大鼠前胃增生的发生率增加。大鼠鼻黏膜炎症发生率增加与氯化汞给药有关。小鼠嗅上皮化生发生率增加也与氯化汞给药有关。
Abavit B、calochlor、升汞、二氯化汞、氯化汞、汞(II)氯化物、二氯化汞、高氯酸汞、升华物、sulem、氯化汞、腐蚀性氯化汞、高氯酸汞、二氯化汞
Fungchex